NANOG and myasthenia gravis: Immunohistochemical analysis has shown that co-expression of Oct-4, along with other transcription factors including Sox2 and NANOG, may be a key genetic driver in the initiation of MGs and it has been identified in both low- and high-grade MG samples [58, 72].